SUVOREXANT - AN OVERVIEW

Stay clear of coadministration with delicate CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and decrease CYP3A substrate dose in accordance with product labeling.rufinamide will lower the extent or impact of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.The effects of est